1251P CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT)

Autor:	S. Mukherjee, S. Lord, R. Harman, D. McIntosh, A. Ooms, M. Parkes, G. Radhakrishna, P.H. Shaw, M.A. Hawkins
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1120
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.07.1369
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d15b28f2cf1751ac752c6f8c64c6027e https://doi.org/10.1016/j.annonc.2022.07.1369 Zobrazit plný text záznamu